{"id":"NCT00149799","sponsor":"Massachusetts General Hospital","briefTitle":"Effectiveness of Escitalopram in the Treatment of Body Dysmorphic Disorder","officialTitle":"Pharmacotherapy Relapse Prevention in Body Dysmorphic Disorder","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-05","primaryCompletion":"2013-03","completion":"2013-03","firstPosted":"2005-09-08","resultsPosted":"2014-11-21","lastUpdate":"2017-12-05"},"enrollment":100,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Anxiety Disorders","Somatoform Disorders"],"interventions":[{"type":"DRUG","name":"Escitalopram","otherNames":["Lexapro"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Escitalopram","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This study's primary aim is to compare time to relapse and relapse rates in responders to acute escitalopram who are then randomized to placebo versus continuation treatment with escitalopram.","primaryOutcome":{"measure":"Phase II Relapse of Body Dysmorphic Disorder (BDD) Symptoms (as Measured by the BDD-YBOCS)","timeFrame":"Phase II: Biweekly for six months after randomization","effectByArm":[{"arm":"Phase II: Escitalopram","deltaMin":18,"sd":null},{"arm":"Phase II: Placebo","deltaMin":40,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.048"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":2},"locations":{"siteCount":2,"countries":["United States"]},"refs":{"pmids":["31505519","29557815"],"seeAlso":["http://www.mghocd.org/bdd"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":100},"commonTop":["Headache","Fatigue","Insomnia","Nausea","Sexual Dysfunction"]}}